UY35921A - NECROSTATIN-1 AND DERIVATIVES AS RETAINERS OF AXONAL DEGENERATION - Google Patents

NECROSTATIN-1 AND DERIVATIVES AS RETAINERS OF AXONAL DEGENERATION

Info

Publication number
UY35921A
UY35921A UY0001035921A UY35921A UY35921A UY 35921 A UY35921 A UY 35921A UY 0001035921 A UY0001035921 A UY 0001035921A UY 35921 A UY35921 A UY 35921A UY 35921 A UY35921 A UY 35921A
Authority
UY
Uruguay
Prior art keywords
necrostatin
retainers
derivatives
axonal degeneration
useful
Prior art date
Application number
UY0001035921A
Other languages
Spanish (es)
Inventor
Washington Nicolás Martínez Alarcón
Felipe Alfredo Court Goldsmith
Original Assignee
Pontificia Universidad Católica De Chile
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pontificia Universidad Católica De Chile filed Critical Pontificia Universidad Católica De Chile
Publication of UY35921A publication Critical patent/UY35921A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Se describen la Necrostatina-1 y compuestos derivados de dicha molécula o sus sales farmacéuticamente aceptables útiles para tratar enfermedades de degeneración axonal. También se divulgan métodos terapéuticos útiles apra tratamientos médicos.Necrostatin-1 and compounds derived from said molecule or its pharmaceutically acceptable salts useful for treating axonal degeneration diseases are described. Useful therapeutic methods for medical treatments are also disclosed.

UY0001035921A 2013-12-30 2014-12-24 NECROSTATIN-1 AND DERIVATIVES AS RETAINERS OF AXONAL DEGENERATION UY35921A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2013003785A CL2013003785A1 (en) 2013-12-30 2013-12-30 Use of necrostatin-1 for the treatment of axonal degeneration induced by acute and chronic damage

Publications (1)

Publication Number Publication Date
UY35921A true UY35921A (en) 2015-06-30

Family

ID=53492873

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035921A UY35921A (en) 2013-12-30 2014-12-24 NECROSTATIN-1 AND DERIVATIVES AS RETAINERS OF AXONAL DEGENERATION

Country Status (4)

Country Link
AR (1) AR098778A1 (en)
CL (1) CL2013003785A1 (en)
UY (1) UY35921A (en)
WO (1) WO2015100511A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11382889B2 (en) 2018-04-19 2022-07-12 Institut D'investigació Biomèdica De Bellvitge (Idibell) NRF2 activators for the prevention and/or treatment of axonal degeneration

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1968583A4 (en) * 2005-12-20 2010-09-15 Harvard College Compounds, screens, and methods of treatment
EP2773341A2 (en) * 2011-10-21 2014-09-10 Massachusetts Eye & Ear Infirmary Compositions comprising necrosis inhibitors, such as necrostatins, alone or in combination, for promoting axon regeneration and nerve function, thereby treating cns disorders

Also Published As

Publication number Publication date
WO2015100511A1 (en) 2015-07-09
CL2013003785A1 (en) 2014-07-11
AR098778A1 (en) 2016-06-15

Similar Documents

Publication Publication Date Title
CY1124436T1 (en) BICYCLIC HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF
CL2017001204A1 (en) 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors
BR112017011972A2 (en) azabicycloctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal disorders
DOP2015000241A (en) BIARIL-AMIDA COMPOUNDS AS CINASA INHIBITORS
CO2017005784A2 (en) Fused bicyclic compounds for the treatment of diseases
CL2015002361A1 (en) Quinazolinic inhibitors of mutated epidermal growth factor receptor activating forms
DOP2015000157A (en) FUSIONED LACTAMAS OF ARILO AND HETEROARILO
BR112017012342A2 (en) bcl-x1 inhibitory compounds and antibody-drug conjugates including the same
EA201500207A1 (en) HETEROAROMATIC COMPOUNDS AS VTK INHIBITORS
BR112016012713A2 (en) METHOD FOR TREATMENT OF CANCER IN A PATIENT IN NEED, AND METHOD OF SELECTING A PATIENT FOR A METHOD OF TREATMENT
BR112015026023A2 (en) 2-aminopyrido [4,3-d] pyrimidin-5-one derivatives and their use as wee-1 inhibitors
DOP2012000257A (en) DERIVATIVES OF THE ACID 1-AMINO-2-CICLOPROPILETILBORONICO
BR112016007467A2 (en) heterocyclic compounds and their uses
MX2016001587A (en) Kdm1a inhibitors for the treatment of disease.
BR112017009552A8 (en) METHODS TO TARGET TRANSCRIPTIONAL CONTROL IN SUPER-ENHANCER REGIONS
EA201591612A1 (en) APPLICATION OF PYRAZOLPYRIMIDIN DERIVATIVES FOR THE TREATMENT OF VIOLATIONS ASSOCIATED WITH PI3Kδ
EA201590343A1 (en) ALKYLPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES
CU20140048A7 (en) NEW PURINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS
CO2017007121A2 (en) Fused bicyclic compounds for the treatment of diseases
UY33863A (en) METHODS AND MEDICINES FOR THE TREATMENT OF ALZHEIMER'S DISEASE
BR112016007396A2 (en) pyridic ketone derivatives, method of preparation thereof and pharmaceutical application thereof
UY35827A (en) TRIAZOLOPIRAZINE DERIVATIVES AS INHIBITORS OF THE BRD4 PROTEIN
CL2015002835A1 (en) New pyridine derivatives
ECSP16008797A (en) DERIVATIVES OF HETEROBICICLOARIL AS RORC2 INHIBITORS AND METHODS OF USE OF THE SAME
PL410665A1 (en) Arginase inhibitors and their therapeutical applications

Legal Events

Date Code Title Description
104 Application deemed to be withdrawn (no substantive examination fee paid)

Effective date: 20201204